  High-dose melphalan and autologous stem cell transplantation ( HDM/SCT) have been used in patients with immunoglobulin light chain ( AL) amyloidosis for over 2 decades now with durable responses , prolonged survival , and decreasing treatment-related mortality. Historically , patients with poorer baseline functional status , advanced age , renal compromise , and cardiac involvement have been treated with a risk-adapted modified conditioning dose of melphalan ( mHDM) of 100 to 140 mg/m